Peptide Receptor Radionuclide Therapy (PRRT) is a nuclear medicine therapy for the systemic treatment of metastasized neuroendocrine tumors (NETs). The results of Netter-1, the first randomized phase III study regarding the efficacy and safety of the radiolabeled somatostatin analogue (SSA) lutetium-177 were published recently in the New England Journal of Medicine.
Lutetium-177, in combination with octreotide, was tested in patients that have been diagnosed with inoperable, well-differentiated, metastatic midgut NETs. The results appear to be impressive in terms of progression-free survival, as patients on Lutetium-177 lived longer without the disease getting worse, compared to patients that took only high-dose of octreotide.
While these are early results that need to be confirmed in the final analysis, they are significant, because currently very few standard treatment op, ions for this category of patients exist. If approved by the FDA, it may be a viable second-line treatment option for gastroenteropancreatic NETs. For more information on the trial read the New England Journal of Medicine article.